X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
apoptosis (533) 533
index medicus (526) 526
humans (513) 513
abt-737 (375) 375
bh3 mimetic abt-737 (343) 343
oncology (285) 285
apoptosis - drug effects (279) 279
sulfonamides - pharmacology (268) 268
cell line, tumor (256) 256
animals (245) 245
proto-oncogene proteins c-bcl-2 - metabolism (235) 235
cancer (219) 219
piperazines - pharmacology (212) 212
biphenyl compounds - pharmacology (211) 211
nitrophenols - pharmacology (210) 210
proto-oncogene proteins c-bcl-2 - antagonists & inhibitors (208) 208
mcl-1 (204) 204
proteins (201) 201
cell biology (182) 182
antineoplastic agents - pharmacology (181) 181
bcl-2 (175) 175
mice (174) 174
biochemistry & molecular biology (139) 139
resistance (134) 134
chronic lymphocytic-leukemia (119) 119
proto-oncogene proteins c-bcl-2 - genetics (117) 117
article (112) 112
leukemia (108) 108
expression (102) 102
chemotherapy (99) 99
inhibitor (99) 99
drug synergism (98) 98
hematology (98) 98
myeloid cell leukemia sequence 1 protein (94) 94
down-regulation (85) 85
bcl-2 family proteins (84) 84
death (81) 81
hemic and lymphatic diseases (81) 81
cell-death (78) 78
apoptosis regulatory proteins - metabolism (77) 77
bh3-only proteins (77) 77
female (75) 75
activation (73) 73
in-vitro (73) 73
bcl-2 family (72) 72
research (72) 72
myeloid cell leukemia sequence 1 protein - metabolism (71) 71
mitochondria (70) 70
acute myeloid-leukemia (68) 68
pharmacology & pharmacy (68) 68
antineoplastic agents - therapeutic use (64) 64
xenograft model antitumor assays (64) 64
in-vivo (63) 63
analysis (61) 61
bcl-x protein - metabolism (61) 61
cell death (60) 60
sensitivity (60) 60
male (59) 59
survival (59) 59
neoplasms - drug therapy (58) 58
bcl-2-like protein 11 (57) 57
cell survival - drug effects (57) 57
proto-oncogene proteins - metabolism (56) 56
bax (55) 55
bcl-2 protein (55) 55
drug resistance, neoplasm (55) 55
bcl-2-associated x protein - metabolism (54) 54
mitochondria - metabolism (54) 54
bcl-2 family-members (53) 53
care and treatment (53) 53
induced apoptosis (53) 53
aniline compounds - pharmacology (52) 52
bcl-x protein - antagonists & inhibitors (52) 52
genetic aspects (52) 52
signal transduction (51) 51
family (50) 50
membrane proteins - metabolism (50) 50
neoplasms - metabolism (50) 50
tumors (50) 50
abt-263 (49) 49
sulfonamides - administration & dosage (49) 49
sulfonamides - therapeutic use (47) 47
acute lymphoblastic-leukemia (46) 46
apoptosis - physiology (46) 46
bim (46) 46
cells (46) 46
health aspects (46) 46
therapy (46) 46
apoptosis - genetics (45) 45
gene expression (45) 45
dose-response relationship, drug (44) 44
neoplasms (44) 44
bcl-2 proteins (43) 43
chemistry, medicinal (43) 43
mitochondria - drug effects (43) 43
bcl-xl (42) 42
lymphomas (41) 41
cancer cells (40) 40
cell lung-cancer (40) 40
cell proliferation - drug effects (40) 40
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


BLOOD, ISSN 0006-4971, 06/2012, Volume 119, Issue 24, pp. 5807 - 5816
The BH3-mimetic ABT-737 and an orally bioavailable compound of the same class, navitoclax (ABT-263), have shown promising antitumor efficacy in preclinical and... 
MULTIPLE-MYELOMA | LUNG-CANCER | ANTAGONIST ABT-737 | FAMILY-MEMBERS | ACUTE LYMPHOBLASTIC-LEUKEMIA | APOPTOTIC RESPONSES | CHRONIC LYMPHOCYTIC-LEUKEMIA | BH3 MIMETIC ABT-737 | HEMATOLOGY | EXPRESSION | INHIBITOR ABT-737 | Leukemia - pathology | Humans | Molecular Targeted Therapy | bcl-2 Homologous Antagonist-Killer Protein - metabolism | Biphenyl Compounds - therapeutic use | Proto-Oncogene Proteins c-bcl-2 - metabolism | Lymphoma - drug therapy | Bcl-2-Like Protein 11 | Biphenyl Compounds - pharmacology | Nitrophenols - pharmacology | bcl-X Protein - antagonists & inhibitors | Nitrophenols - therapeutic use | Protein Binding - drug effects | Cytoprotection - drug effects | Lymphoma - pathology | Membrane Proteins - metabolism | Cell Death - drug effects | Gene Expression Regulation, Neoplastic - drug effects | Leukemia - genetics | Proto-Oncogene Proteins - metabolism | Aniline Compounds - pharmacology | bcl-2-Associated X Protein - metabolism | Etoposide - pharmacology | Leukemia - drug therapy | Lymphoma - genetics | Mutant Proteins - metabolism | Piperazines - therapeutic use | Sulfonamides - pharmacology | Piperazines - pharmacology | Apoptosis Regulatory Proteins - metabolism | Animals | Sulfonamides - therapeutic use | Myeloid Cell Leukemia Sequence 1 Protein | Apoptosis Regulatory Proteins - antagonists & inhibitors | Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors | Mice | Aniline Compounds - therapeutic use | bcl-X Protein - metabolism | Drug Resistance, Neoplasm - drug effects
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2012, Volume 30, Issue 5, pp. 488 - 496
Purpose BCL2 overexpression is a hallmark of chronic lymphocytic leukemia (CLL). The novel BH3 mimetic navitoclax (ABT-263) specifically inhibits BCL2 and... 
APOPTOSIS | LYMPHOMA-CELLS | ANTAGONIST ABT-737 | ONCOLOGY | SENSITIVITY | RESISTANCE | BH3 MIMETIC ABT-737 | CANCER | CHEMOTHERAPY | CELL-DEATH | FAMILY | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Male | Antineoplastic Agents - administration & dosage | Leukemia, Lymphocytic, Chronic, B-Cell - genetics | Proto-Oncogene Proteins c-bcl-2 - metabolism | Bcl-2-Like Protein 11 | Antineoplastic Agents - adverse effects | Biomarkers, Tumor - metabolism | Female | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Membrane Proteins - metabolism | Aniline Compounds - administration & dosage | Chromosome Deletion | Proto-Oncogene Proteins - metabolism | Aniline Compounds - pharmacology | Drug Administration Schedule | Administration, Oral | In Situ Hybridization, Fluorescence | Treatment Outcome | Thrombocytopenia - chemically induced | Aniline Compounds - pharmacokinetics | Sulfonamides - pharmacology | Sulfonamides - pharmacokinetics | Apoptosis Regulatory Proteins - metabolism | Leukemia, Lymphocytic, Chronic, B-Cell - metabolism | Myeloid Cell Leukemia Sequence 1 Protein | Sulfonamides - adverse effects | Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Aniline Compounds - adverse effects | Sulfonamides - administration & dosage | Hema7 | ORIGINAL REPORTS
Journal Article
Cancer Cell, ISSN 1535-6108, 02/2013, Volume 23, Issue 2, pp. 139 - 141
ABT-199 is a new selective small molecule inhibitor of BCL-2 that appears to spare platelets while achieving potent antitumor activity. Assays that can predict... 
ABT-737 | CHRONIC LYMPHOCYTIC-LEUKEMIA | ONCOLOGY | FAMILY | CELL BIOLOGY
Journal Article
BLOOD, ISSN 0006-4971, 02/2012, Volume 119, Issue 5, pp. 1321 - 1322
Journal Article
BLOOD, ISSN 0006-4971, 08/2011, Volume 118, Issue 6, pp. 1663 - 1674
BH3 mimetics are a new class of proapoptotic anticancer agents that have shown considerable promise in preclinical animal models and early-stage human trials.... 
BCL-2 | ADHESION | IN-VITRO | PHOSPHORYLATION | PROTEIN-KINASE | ABT-737 | SHAPE CHANGE | THERAPIES | HEMATOLOGY | CANCER | SMALL-MOLECULE INHIBITOR
Journal Article
BLOOD, ISSN 0006-4971, 04/2008, Volume 111, Issue 7, pp. 3701 - 3713
The activated B cell-like (ABC) subgroup of diffuse large B-cell lymphoma (DLBCL) is characterized by constitutive activation of the nuclear factor-kappa B... 
APOPTOSIS | IN-VIVO | STAT3 | GENE-EXPRESSION | DIFFERENTIATION | BH3 MIMETIC ABT-737 | INHIBITOR | PROTEINS | HEMATOLOGY | CANCER | FAMILY | Neoplasia
Journal Article
Clinical cancer research : an official journal of the American Association for Cancer Research, ISSN 1078-0432, 8/2015, Volume 21, Issue 16, pp. 3705 - 3715
Journal Article
Cellular Signalling, ISSN 0898-6568, 09/2012, Volume 24, Issue 9, pp. 1803 - 1809
Small-molecule cell-permeable Bcl-2/Bcl-xL antagonist ABT-737 has recently emerged as a novel cancer therapeutic agent because it potently induces apoptosis in... 
ABT-737 | Norcantharidin | Hepatocelluar carcinoma cells | Apoptosis | ACTIVATION | BCL-XL | EFFICIENTLY INDUCES APOPTOSIS | DOWN-REGULATION | HEPATOMA-CELLS | BH3 MIMETIC ABT-737 | CELL BIOLOGY | BREAST-CANCER | PROSTATE-CANCER CELLS | BAX | INHIBITOR ABT-737 | Transcription, Genetic - drug effects | Apoptosis - drug effects | Humans | Myeloid Cell Leukemia Sequence 1 Protein - metabolism | Piperazines - chemistry | Nitrophenols - chemistry | Dose-Response Relationship, Drug | Carcinoma, Hepatocellular - drug therapy | Biphenyl Compounds - pharmacology | Nitrophenols - pharmacology | Liver Neoplasms - pathology | Antineoplastic Agents - pharmacology | Biphenyl Compounds - chemistry | Myeloid Cell Leukemia Sequence 1 Protein - antagonists & inhibitors | Sulfonamides - chemistry | Bridged Bicyclo Compounds, Heterocyclic - chemistry | Liver Neoplasms - drug therapy | Antineoplastic Agents - chemistry | Sulfonamides - pharmacology | Piperazines - pharmacology | Myeloid Cell Leukemia Sequence 1 Protein - genetics | Bridged Bicyclo Compounds, Heterocyclic - pharmacology | Carcinoma, Hepatocellular - pathology | Cell Line, Tumor | Cell Proliferation - drug effects | Transcription, Genetic - genetics | Drug Screening Assays, Antitumor | Cytochrome c | Liver cancer | Carcinoma | Genetic aspects | Hepatoma | Cancer | Drugs | Cellular | Effectiveness | Pathways | Activation | Signalling
Journal Article
The EMBO Journal, ISSN 0261-4189, 05/2007, Volume 26, Issue 10, pp. 2527 - 2539
The anti-apoptotic proteins Bcl-2 and Bcl-X-L bind and inhibit Beclin-1, an essential mediator of autophagy. Here, we demonstrate that this interaction... 
Bcl-2 | autophagy | PROTEIN | PHOSPHORYLATION | mitochondria | BIOCHEMISTRY & MOLECULAR BIOLOGY | apoptosis | AUTOPHAGIC CELL-DEATH | MACROAUTOPHAGY | BH3 MIMETIC ABT-737 | CELL BIOLOGY | GENE | Bax | TUMOR-SUPPRESSOR | C-ELEGANS | TUMORIGENESIS
Journal Article
Journal Article
Journal Article
Journal Article
Cell Death and Differentiation, ISSN 1350-9047, 04/2012, Volume 19, Issue 4, pp. 623 - 632
Journal Article
Journal of Biological Chemistry, ISSN 0021-9258, 03/2012, Volume 287, Issue 13, pp. 10224 - 10235
Journal Article
BLOOD, ISSN 0006-4971, 04/2009, Volume 113, Issue 18, pp. 4403 - 4413
ABT-737 and its orally active analog, ABT-263, are rationally designed inhibitors of BCL2 and BCL-X-L. ABT-263 shows promising activity in early phase 1... 
APOPTOSIS | DEPENDENT TRANSCRIPTION | FAMILY-MEMBERS | MCL-1 | DOWN-REGULATION | HISTONE DEACETYLASE INHIBITORS | BH3 MIMETIC ABT-737 | HEMATOLOGY | NF-KAPPA-B | EXPRESSION | CELL-DEATH
Journal Article
CANCER LETTERS, ISSN 0304-3835, 06/2014, Volume 348, Issue 1-2, pp. 38 - 49
We previously showed that BcI-x(L) and Mcl-1 cooperatively protect platinum-resistant ovarian cancer cells from apoptosis. Here we assessed the anticancer... 
CANCER-CELLS | INDUCED APOPTOSIS | Bim | NVP-BEZ235 | ABT-737 | BCL-2 FAMILY PROTEINS | ACQUIRED-RESISTANCE | DOWN-REGULATION | BH3 MIMETIC ABT-737 | PI3K INHIBITION | Ovarian cancer | TRANSLATIONAL CONTROL | Mcl-1 | ERK1/2 | MEK INHIBITION | ONCOLOGY | MYELOID-LEUKEMIA
Journal Article
LEUKEMIA, ISSN 0887-6924, 02/2016, Volume 30, Issue 2, pp. 351 - 360
The pro-survival Bcl-2 family member Mcl-1 is expressed in chronic lymphocytic leukaemia (CLL), with high expression correlated with progressive disease. The... 
SURVIVAL | CLL | FAMILY-MEMBER MCL-1 | ONCOLOGY | ANTITUMOR SUBSTANCES | NOXA/MCL-1 BALANCE | MUTATIONS | HEMATOLOGY | PHASE-I | EXPRESSION | SPLICING FACTOR | ABT-737 RESISTANCE
Journal Article
Biochemical Society Transactions, ISSN 0300-5127, 04/2016, Volume 44, Issue 2, pp. 371 - 376
Chimaeric antigen receptor (CAR) T-cells have shown